Cancer Therapies From Dendreon and AEterna Zentaris Poised to Boost Profits
February 27 2012 - 8:20AM
Marketwired
Advances in cancer screening and treatment has caused the death
rate from cancer to drop in recent years. Cancer death rates
dropped by 1.8 percent per year in men and 1.6 percent per year in
women between 2004 and 2008, according to the American Cancer
Society's annual report on cancer statistics. Five Star Equities
examines the outlook for companies in the Biotechnology industry
and provides equity research on Dendreon Corporation (NASDAQ: DNDN)
and AEterna Zentaris, Inc. (NASDAQ: AEZS) (TSX: AEZ). Access to the
full company reports can be found at:
www.fivestarequities.com/DNDN
www.fivestarequities.com/AEZS
Death rates fell in all four of the most common cancers, lung,
colon, breast and prostate, with lung cancer accounting for nearly
40 percent of the total drop in men and breast cancer account for
34 percent of the total decline in women, the American Cancer
Society report finds.
The U.S. FDA has been approving cancer drugs at a faster rate
than its European counterpart (the EMA), Friends of Cancer Research
reports. Between 2003 and 2010, the FDA not only approved more new
cancer drugs than did the EMA, it approved these drugs more
quickly: of 23 drugs approved by both agencies, the median time
from marketing submission to FDA approval was 182 days vs. EMA
approval of 350 days according to the report.
Five Star Equities releases regular market updates on the
biotechnology industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.fivestarequities.com
and get exclusive access to our numerous stock reports and industry
newsletters.
Aeterna Zentaris Inc. operates as a late-stage drug development
company specialized in oncology and endocrine therapy. The
company's lead oncology compounds include perifosine, which is in
Phase 3 registration trial for refractory advanced colorectal
cancer and multiple myeloma; and AEZS-108, a doxorubicin-targeted
conjugate in Phase II for the treatment of ovarian, endometrial,
castration refractory prostate, and refractory bladder cancer.
Dendreon Corporation, a biotechnology company, engages in the
discovery, development, and commercialization of therapeutics to
enhance cancer treatment options for patients.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.fivestarequities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Five Star Equities Email Contact
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024